Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up Following Analyst Upgrade

Bicara Therapeutics Inc. (NASDAQ:BCAXGet Free Report)’s share price gapped up before the market opened on Monday after HC Wainwright raised their price target on the stock from $42.00 to $45.00. The stock had previously closed at $11.61, but opened at $12.03. HC Wainwright currently has a buy rating on the stock. Bicara Therapeutics shares last traded at $12.00, with a volume of 55,601 shares changing hands.

BCAX has been the topic of a number of other reports. Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective on the stock. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. TD Cowen assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating for the company. Stifel Nicolaus initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price on the stock. Finally, Cantor Fitzgerald assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating for the company. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $43.75.

Get Our Latest Analysis on Bicara Therapeutics

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Turn Management LLC bought a new stake in shares of Bicara Therapeutics in the third quarter worth $14,324,000. The Manufacturers Life Insurance Company bought a new stake in Bicara Therapeutics during the 3rd quarter worth about $582,000. FMR LLC acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $57,913,000. Walleye Capital LLC bought a new stake in Bicara Therapeutics during the third quarter worth about $809,000. Finally, Vestal Point Capital LP bought a new position in Bicara Therapeutics in the third quarter valued at approximately $10,825,000.

Bicara Therapeutics Price Performance

The company has a 50 day moving average of $16.79.

Bicara Therapeutics (NASDAQ:BCAXGet Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

See Also

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.